Advances in the management of gastrointestinal cancers - An upcoming role of immune checkpoint blockade

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Goel, Gaurav ^a   Sun, Weijing ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Checkpoint inhibitors; Gastrointestinal cancers; Immunotherapy; Nivolumab; PD 1; PD L1; Pembrolizumab

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CANCER VACCINE; CD40 ANTIBODY; CRS 207; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; SORAFENIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CHEMORADIOTHERAPY; COLORECTAL CANCER; DECREASED APPETITE; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FATIGUE; HUMAN; HYPERAMYLASEMIA; HYPOXIA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DISEASE; LYMPHOCYTOPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PNEUMONIA; PRURITUS; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; STOMACH CARCINOMA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR IMMUNITY; GASTROINTESTINAL TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY;

EID: 84937037333     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0185-6     Document Type: Review

References (18)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
2. Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6:74.
3. Han EQ, Li XL, Wang CR, Li TF, Han SY. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol. 2013;6:47.
4. Li Z, Chen L, Rubinstein MP. Cancer immunotherapy: are we there yet? Exp Hematol Oncol. 2013;2:33.
5. Ehrlich D, Wang B, Lu W, Dowling P, Yuan R. Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma. J Hematol Oncol. 2014;7:91.
6. Goel G, Sun W. Cancer immunotherapy in clinical practice-the past, present, and future. Chin J Cancer. 2014;33:445-57.
7. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513:202-209.
8. Bang YJ, Chung HC, Shankaran V, Geva R, Catenacci DVT, Gupta S, et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol 2015, 33(suppl):abstr 4001.
9. Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Yuan S, Koshiji M, et al. Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: preliminary results from KEYNOTE-028. J Clin Oncol 2015, 33(suppl):abstr 4010.
10. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417-22.
11. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43-51.
12. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:3509-20.
13. El-Khoueiry AB, Melero I, Crocenzi TS, Welling TH, Yau TC, Yeo W, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015, 33(suppl):abstr LBA101.
14. Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44.
15. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612-6.
16. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828-33.
17. Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014;7:70.
18. Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park). 2014;28 Suppl 3:39-48.